Lung Cancer Content
Continuing the momentum in SCLC: Exploring second-line and novel therapy options
MDT specialists discuss the current and emerging second-line treatment options for patients with extensive-stage small cell lung cancer (ES-SCLC)
- Describe the current and emerging second-line treatment options for patients with SCLC
- Identify patient- and disease-related factors that affect treatment decisions for patients with SCLC in the second-line setting
- Describe strategies to manage adverse events for patients with SCLC in the second-line treatment setting
Daniel Steinfort, WCBIP 2022: Findings from the SEISMIC Study
The SEISMIC study investigated lymph nodes by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with locally advanced non-small cell lung cancer (NSCLC). touchRESPIRATORY were delighted to speak with Dr. Daniel Steinfort (Royal Melbourne Hospital, Melbourne, Australia) to learn more around the aims, design and findings from the study and the importance of these findings […]
Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care
Watch leading specialists involved in the multidisciplinary care of patients with rare and unusual neuroendocrine tumours discuss new and emerging approaches for diagnosis and treatment.
- Recognize the role of the MDT in addressing diagnostic and treatment challenges associated with rare and unusual neuroendocrine tumours (NETs)
- Evaluate the factors guiding treatment selection and clinical management decisions in rare and unusual NETs
- Appraise the efficacy and safety of new and emerging treatment options for rare and unusual NETs
Paulo Rodrigues Santos, ERS 2022: Immunosuppressive Factors Affecting Anti-PD-1 Therapy in Phase IIIB/IV Non-small Cell Lung Cancer
touchRESPIRATORY caught up with Dr. Paulo Rodrigues Santos (University of Coimbra, Coimbra, Portugal) to discuss the challenges associated with the use of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer, the cellular and plasmatic immunosuppressive factors that affect the outcome of anti-PD-1 therapy and the data supporting the strategies used to overcome these immunosuppressive […]
Investigating KRASG12C inhibitors: How might they improve outcomes for patients with solid tumours?
Prof. Tony Mok discusses the role of KRAS mutations in solid tumours and the impact of KRASG12C inhibitors on patient outcomes.
- Describe the role of KRAS in tumourigenesis and the implications of the KRASG12C mutation for patients with solid tumours
- Evaluate the efficacy and safety of KRASG12C inhibitors in advanced and metastatic KRAS-mutated solid tumours
- Formulate strategies to overcome intrinsic or acquired resistance to KRASG12C-directed therapies
Gerard A. Silvestri, CHEST 2022: Managing Complications in the Treatment of Lung Cancer (Part 2)
There are many common complications encountered during the treatment of lung cancer. touchRESPIRATORY were delighted to speak with Professor Gerard A. Silvestri (Medical University of South Carolina, Charleston, SC, USA) to learn more around the recommendations for management of complications during lung cancer treatment and what unmet needs still remain. ‘Diagnosis and Management of Complications in the […]
Gerard A. Silvestri, CHEST 2022: Managing Complications in the Treatment of Lung Cancer (Part 1)
There are many common complications encountered during the treatment of lung cancer. touchRESPIRATORY were delighted to speak with Professor Gerard A. Silvestri (Medical University of South Carolina, Charleston, SC, USA) to learn more around the diagnosis, challenges and management of these complications. ‘Diagnosis and Management of Complications in the Treatment of Lung Cancer.’ was presented […]
Rolof Gijtenbeek, ERS 2021: The NVALT 17 Study
We were delighted to talk with Dr Rolof Gijtenbeek (Medical Center Leeuwarden, Leeuwarden, The Netherlands) around his abstract on ‘Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.‘, (Presentation ID 4324) which was presented at […]
Optimizing frontline immunotherapy for advanced NSCLC
Watch this two-part activity exploring recent developments on the use of frontline immunotherapeutic strategies in patients with advanced non-small cell lung cancer (NSCLC). Filmed following the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and European Society for Medical Oncology (ESMO) Congress 2021. Part 1: Watch thoracic oncology expert Prof. Edward Garon review key data from the 2021 ASCO Annual Meeting and ESMO Congress 2021 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
- Summarize recent data evaluating frontline single-agent immunotherapy or combination strategies for advanced NSCLC
- Assess potential biomarkers that may be used to identify patients with advanced NSCLC who may benefit from frontline immunotherapy
- Outline effective management strategies using frontline immunotherapeutic strategies for patients with advanced NSCLC
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!